

X-halo by DELMEDICA

Delmedica's award-winning and revolutionary breath thermometer measures up mass-market entry.

As part of Delmedica's ongoing program of protecting its intellectual property, the X-halo brand name and logotype was recently granted its registered trademark status in the USA.

Following ISO 13485 certification by the next quarter, X-halo also expects to receive Class 2 medical device approval from both the European Union and the United States within three months.

“Europe’s CE and USA’s FDA markings will provide a hugely significant fillip in capitalising upon what is already a compelling and evolving, peer-reviewed story.”

Dr. Jaswinder Gill, Managing Director of Delmedica.

“Our market strategy has always been a top-down approach. To first gain product advocacy by the medical profession through substantiated testing, results and product usage. Secondly, to use this as the platform from which to activate distribution and sales channels that is ultimately targeted towards the mass. The second phase is what we're currently gearing up for; in readiness for CE and FDA approval.”

Indeed, X-halo's exposure to the clinical and medical communities has seen an increase of interest and enquiry through peer-to-peer referrals: Driven, primarily, by the uniqueness of the technology, its future applications potential and the enormous benefits associated with viral, metabolic and bacterial diagnostics as a whole.

“X-halo represents an extraordinary leap in predictive diagnosis and monitoring; providing a medical professional, an individual, a family,



company or school for example with the means to accurately measure and manage the onset of symptoms far earlier than traditional means.”

X-halo detects and records the inflammation of lungs, through miniscule rises in temperature, BEFORE the onset of an Asthma attack thus allowing for more efficient management of this crippling disease and fewer fatalities. No other technology or methodology is able to achieve this: making X-halo truly unique and cutting-edge.


Continues Dr. Gill,

“X-halo is a precision technology that will be as much an everyday household appliance as it is an essential tool for the practitioner. It is designed and will be marketed as such.”

Though X-halo is currently positioned as an Asthma aid the product may already be used to detect the early onset of, potentially, any viral or bacterial upper respiratory tract infection.

“At the outset we wished to focus our attentions on a disease that is already well-documented, highly prevalent, in fact proliferating and which helped showcase the effectiveness of the product when placed in context with the need for predictive monitoring and pre-emptive treatment.”

Asthma represents an enormous market; with an estimated 300 million diagnosed sufferers worldwide. As an illustration of the global



concern surrounding Asthma the **World Health Organisation (WHO)** has adopted it as its first non-infectious disease initiative.

Coupled with this a number of pharmaceutical companies and clinical trial organisations are already using X-halo in their quests to develop more effective drugs to treat asthma.

The Singapore Economic Development Board recognise the enormous potential of the X-halo technology. They will be providing support to Delmedica to develop product lines that target various medical conditions and market applications.

Examples include early detection of **viral infections**, such as flu strains, and how such systems may be applied to government institutions, airports, armed forces and major corporations. X-halo may also be used for **fertility treatment**; detecting the exact moment of ovulation and allowing for more precise family planning. Recent studies show that X-halo can detect the presence of **bacterial infections**, such as Tuberculosis, BEFORE clinical symptoms are realised. Research will also be conducted on temperature increases or decreases generated by **metabolic disorders** such as hyper or hypo-thyroidism and how X-halo can be used in their management. The same applies to certain **psychological conditions** as with Schizophrenia.

Delmedica has received an approach, fully funded by a major pharmaceutical company, to develop a nasal inflammation measurement device. Details will be released in due course.

X-halo has recently won Gold in the highly coveted, and globally recognised, **IF Design Awards**, for its aesthetic, and functional excellence. An accolade that Delmedica and its designers, Philips Electronics, are understandably proud of.

Dr. Gill adds:

“Such an award simply underscores what we, as well as the medical industry, already understand: We have a ground-breaking product that will breath new life into those that support it, invest in it, distribute and sell it but also, crucially, to all those millions of sufferers that will benefit from the intrinsic use of it.”



Delmedica have recently appointed **Monopoly Design** to undertake its branding, media and marketing activities for its Business to Business ('B2B') and Business to Commerce ('B2C') platforms. Phase One's B2B initiative is scheduled for completion by July 2009.

ABOUT DELMEDICA INVESTMENTS

Based in Singapore, Delmedica Investments are a specialist funding company offering investors access to the immense potential of the global biotechnology industry. Via their impressive resources and network of health care professionals, Delmedica identify new opportunities with tangible commercial potential, opportunities that represent low risk, high-growth and clear exit strategies. Recently the healthcare industry replaced technology as the fastest growing sector in the U.S., now accounting for 12% of the total U.S. economy. Find out how Delmedica offers the investor access to innovations that represent the future of the health care industry.

TO ORDER YOUR X-halo VISIT
www.x-halo.com

FOR MORE INFORMATION PLEASE CONTACT
Jaswinder Gill

Delmedica Investments (Singapore) Pte. Ltd
7 Temasek Boulevard, #06-01, Suntec Tower 1, Singapore 038987
Phone: +65 6415 3102 Fax: +65 6415 3108
E-mail: jas.gill@delmedicainvestments.com
www.delmedicainvestments.com

